Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

496
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
496
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

545
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
545
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

489
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
489
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

318
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
318
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

303
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
303
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

740
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
740

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.

Annals of hematology·2026
Same author

Anti-progestin therapy targets hallmarks of breast cancer risk.

Nature·2025
Same author

Retraction notice to "17β-Estradiol, Genistein, and 4-Hydroxytamoxifen Induce the Proliferation of Thyroid Cancer Cells through the G Protein-Coupled Receptor GPR30" [Mol Pharmacol 70 (2006) 1414-1423].

Molecular pharmacology·2025
Same author

Adipocyte‑derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross‑talk between cancer cells and the tumor microenvironment.

International journal of oncology·2025
Same author

Interplay between Leptin and Stearoyl-CoA Desaturase 1 in Estrogen Receptor-Positive Breast Cancer Cells.

The American journal of pathology·2025
Same author

Beneath the surface in autoimmune hemolytic anemia: pathogenetic networks, therapeutic advancements and open questions.

Frontiers in immunology·2025
Same journal

Correction: Reis et al. Bioinks Enriched with ECM Components Obtained by Supercritical Extraction. <i>Biomolecules</i> 2022, <i>12</i>, 394.

Biomolecules·2026
Same journal

Correction: Kim, K.-H.; Yoo, B.C. Gintonin as a Lysophosphatidic Acid-Enriched GPCR Ligand System: Molecular Architecture and Receptor Pharmacology in <i>Panax ginseng</i>. <i>Biomolecules</i> 2026, <i>16</i>, 465.

Biomolecules·2026
Same journal

Correction: Bastyte et al. The Association of Vitamin D Receptor Gene Polymorphisms with Vitamin D, Total IgE, and Blood Eosinophils in Patients with Atopy. <i>Biomolecules</i> 2024, <i>14</i>, 212.

Biomolecules·2026
Same journal

AtHSPR Plays a Positive Role in Arabidopsis Resistance Against <i>Pseudomonas syringae</i> pv. <i>tomato</i> DC3000 by Interacting with TOP1.

Biomolecules·2026
Same journal

CYTH4 Facilitates Renal Cell Carcinoma via Enhancing Proliferation and Likely Immune Evasion.

Biomolecules·2026
Same journal

Integrated Immune-Gut Profiling Identifies an Exploratory Pediatric Inflammatory Intestinal Profile Associated with Food-Specific IgG Reactivity.

Biomolecules·2026
See all related articles

Related Experiment Video

Updated: Oct 25, 2025

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.3K

Leptin-Activity Modulators and Their Potential Pharmaceutical Applications.

Marianna Greco1, Marzia De Santo1, Alessandra Comandè1

  • 1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.

Biomolecules
|August 6, 2021
PubMed
Summary
This summary is machine-generated.

Leptin hormone regulates body weight, reproduction, and immunity. Leptin signaling modulators, including antibodies and nanobodies, show promise for treating cancers and other diseases.

Keywords:
leptinleptin mutantsleptin receptorleptin-activity modulatorsmonoclonal antibodiesnanobodiespeptide antagonists

More Related Videos

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.7K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

189

Related Experiment Videos

Last Updated: Oct 25, 2025

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

12.3K
Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

2.7K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

189

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Leptin, a hormone from adipose tissue, controls body weight, energy expenditure, reproduction, immunity, and bone metabolism.
  • Leptin also has angiogenic and mitogenic effects on peripheral organs.
  • Leptin's functions are mediated by its receptor; imbalances (excess, deficiency, resistance) link to pathologies like cancer and autoimmune diseases.

Purpose of the Study:

  • To review updated leptin-activity modulators.
  • To highlight their therapeutic potential in cancer and other leptin-related diseases.

Main Methods:

  • Review of scientific literature on leptin signaling modulators.
  • Categorization of modulators into leptin mutants, peptide-based modulators, monoclonal antibodies, and nanobodies.

Main Results:

  • Leptin and its receptor are crucial drug targets.
  • Leptin signaling modulators offer a promising therapeutic strategy.
  • Various modulators, including antibodies and nanobodies, are discussed.

Conclusions:

  • Leptin signaling modulation is a key strategy for treating cancers and other diseases.
  • Development of specific modulators like monoclonal antibodies and nanobodies is advancing.
  • Targeting leptin pathways holds significant therapeutic potential.